Evidence map›Paper›PMID 31023007›Full record

ArticleGut and liver2019

A Proposal for Modification of the Barcelona Clinic Liver Cancer Staging System Considering the Prognostic Implication of Performance Status.

Hyo Jung Cho, Soon Sun Kim, So Young Kang, Min Jae Yang, Choong Kyun Noh, Jae Chul Hwang, Sun Gyo Lim, Sung Jae Shin, Kee Myung Lee, Byung Moo Yoo and 5 more

Abstract readMulticenter Study
In one paragraph

Article in Gut and liver, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Hyo Jung ChoDepartment of Gastroenterology, Ajou University School of Medicine, Suwon, Korea.
Soon Sun KimDepartment of Gastroenterology, Ajou University School of Medicine, Suwon, Korea.
So Young KangOffice of Biostatistics, Ajou University School of Medicine, Suwon, Korea.
Min Jae YangDepartment of Gastroenterology, Ajou University School of Medicine, Suwon, Korea.
Choong Kyun NohDepartment of Gastroenterology, Ajou University School of Medicine, Suwon, Korea.
Jae Chul HwangDepartment of Gastroenterology, Ajou University School of Medicine, Suwon, Korea.
Sun Gyo LimDepartment of Gastroenterology, Ajou University School of Medicine, Suwon, Korea.
Sung Jae ShinDepartment of Gastroenterology, Ajou University School of Medicine, Suwon, Korea.
Kee Myung LeeDepartment of Gastroenterology, Ajou University School of Medicine, Suwon, Korea.
Byung Moo YooDepartment of Gastroenterology, Ajou University School of Medicine, Suwon, Korea.
Kwang Jae LeeDepartment of Gastroenterology, Ajou University School of Medicine, Suwon, Korea.
Jin Hong KimDepartment of Gastroenterology, Ajou University School of Medicine, Suwon, Korea.
Sung Won ChoDepartment of Gastroenterology, Ajou University School of Medicine, Suwon, Korea.
Jae Youn CheongDepartment of Gastroenterology, Ajou University School of Medicine, Suwon, Korea.ORCID 0000-0001-6246-1783
Korean Liver Cancer Association

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/Aims: Barcelona Clinic Liver Cancer (BCLC) C stage demonstrates considerable heterogeneity because it includes patients with either symptomatic tumors (performance status [PS], 1-2) or with an invasive tumoral pattern reflected by the presence of vascular invasion (VI) or extrahepatic spread (EHS). This study aimed to derive a more relevant staging system by modification of the BCLC system considering the prognostic implication of PS. Methods: A total of 7,501 subjects who were registered in the Korean multicenter hepatocellular carcinoma (HCC) registry database from 2008 to 2013 were analyzed. The relative goodness-of-fit between staging systems was compared using the Akaike information criterion (AIC) and integrated area under the curve (IAUC). Three modified BCLC (m-BCLC) systems (#1, #2, and #3) were devised by reducing the role of PS. Results: As a result, the BCLC C stage, which includes patients with PS 1-2 without VI/EHS, was reassigned to stage 0, A, or B according to their tumor burden in the m-BCLC #2 model. This model was identified as the most explanatory and desirable model for HCC staging by demonstrating the smallest AIC (AIC=70,088.01) and the largest IAUC (IAUC=0.722), while the original BCLC showed the largest AIC (AIC=70,697.17) and the smallest IAUC (IAUC=0.705). The m-BCLC #2 stage C was further subclassified into C1, C2, C3, and C4 according to the Child-Pugh score, PS, presence of EHS, and tumor extent. The C1 to C4 subgroups showed significantly different overall survival distribution between groups (p<0.001). Conclusions: An accurate and relevant staging system for patients with HCC was derived though modification of the BCLC system based on PS.

Indexed as

Carcinoma, HepatocellularFemaleHepatitis B, ChronicHepatitis C, ChronicHumansLiver NeoplasmsMaleMiddle AgedNeoplasm StagingPrognosisRegistriesRepublic of KoreaSurvival AnalysisTumor BurdenBarcelona Clinic Liver Cancer StagingEastern Cooperative Oncology Group performance statusHepatocellular carcinomaStage

Identifiers

PMID31023007
PMCPMC6743810

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.